EP1154770A2 — Premixed formulation of piperacillin sodium and tazobactam sodium injection
Assigned to Baxter International Inc · Expires 2001-11-21 · 24y expired
What this patent protects
The present invention provides a premixed form of a buffered piperacillin product having a near neutral pH and capable of a shelf life of at least nine months, with freezer storage (-20° C. or lower), or a refrigerated shelf life of up to 14 days at about 5° C. The piperacillin m…
USPTO Abstract
The present invention provides a premixed form of a buffered piperacillin product having a near neutral pH and capable of a shelf life of at least nine months, with freezer storage (-20° C. or lower), or a refrigerated shelf life of up to 14 days at about 5° C. The piperacillin may additionally contain a tazobactam component to inactivate beta-lactamases that commonly cause resistance to penicillins, allowing the piperacillin component to destroy susceptible bacteria. With the addition of dextrose, the premixed composition is physiologically isosmotic.
Drugs covered by this patent
Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.
Track this patent
Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.